Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion Therapy for Stage III Unresectable NSCLC
ChiCTR2600126424Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: 2-year event-free survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600126424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126424.